



# Usefulness of Homoeopathic medicines in Poly-cystic ovarian syndrome-Case series

# Bhuvaneswari Rajachandrasekar 1\*, Nilina P Ravindran 2

Research officer (Homoeopathy) Associate Professor, Dept of Psychiatry,
 PG Scholar, Practice of Medicine,
 National Homoeopathy Research Institute in Mental Health, Kottayam, Kerala, India.

### **Abstract:**

Polycystic ovarian syndrome (PCOS) is a common endocrine disorder that affects multiple aspect of women's health during the reproductive age group. PCOS exerts a negative impact on female identity and contributes to deterioration of Quality of life. Homoeopathy is a complementary system of medicine that can be used safely without any known side-effects. This article mainly highlights the importance of using individualized homoeopathic medicines in PCOS. Three cases of women in reproductive age with PCOS were treated with individualized homeopathic medicines. Each case was reported according to the criteria set out in the HOM-CASE guidelines. The improvement is evaluated from the regularity of the menstrual cycle by assessing with the PCOS questionnaire, Modified Naranjo Criteria for Homoeopathy (MONARCH), and also from the ultrasonography (USG) reports. Marked improvement was observed in all three cases of PCOS. The irregular menstrual cycles and other associated symptoms became normal, along with a resolution of cysts in ovaries as noticed in ultrasonography. All cases improved within 6 to 18 months of treatment. The Modified Naranjo Criteria total score was +8/13, +9/13, +8/13 for the cases, which indicates a positive causal attribution of homeopathy in relieving the symptoms of PCOS. These case reports suggest a significant role of individualized homeopathic medicines in PCOS. The improvement is evident at the symptomatic level, and also in Ultrasonography.

**Key words**: Homoeopathy, MONARCH, Polycystic ovarian syndrome.

Received: 08.10.2021 Revised: 18.11.2021 Accepted: 10.12.2021 Published: 25.12.2021

### **Quick Response code**



### \*Corresponding Author:

Dr. Bhuvaneswari Rajachandrasekar


Research officer (Homoeopathy), Associate Professor, Dept. of Psychiatry, National Homoeopathy Research Institute in Mental Health, Kottayam, Kerala, India.

E-mail: <u>dr.bhuvaneswarir@gmail.com</u>

### Introduction

PCOS is a heterogeneous endocrine disorder that affects women of reproductive age group worldwide.<sup>[1]</sup> PCOS is having multifactorial pathology which is influenced by genetic,

endocrine, and environmental factors.<sup>[2]</sup> It is the usual cause of menstrual irregularities and infertility among females.<sup>[3]</sup>During the start of puberty majority of girls have anovulatory





menstruation. Menses can be even irregular for the first 2 years of puberty.<sup>[4]</sup>

According to WHO, the prevalence of PCOS around the world is increasing and about 116 million women of reproductive age are affected across the world. [5] The prevalence according to NIH/NICHD criteria forms 4%–8% and as high as 15%–20% according to the ESHRE/ASRM criteria.

Due to changes in lifestyles and diet, the prevalence rate in India has also become similar. [6,7] Studies suggest that the burden of PCOS is considerably lower among rural Indian adolescents when compared to their urban counterparts.[8] The current incidence of PCOS is fast growing due to changes in lifestyle and stress. It is becoming a common problem amongst adolescence, developing soon after puberty. Hirsutism and obesity produce adverse cosmetic and psychological consequences which can reduce the quality of life. Infertility emerges as one of the major predictors affecting overall Health Related Quality of Life (HRQOL) in PCOS cases. [9-10] Diagnosis of PCOS at an earlier stage and proper interventions with diet and lifestyle management could prevent the patients from complications like cardiovascular diseases. [11] Cases were diagnosed based on Rotterdam criteria and USG findings.[12]

In a pilot case-control study about the Evaluation of homoeopathic treatment in polycystic ovary syndrome, it was found that homoeopathic interventions with lifestyle modification showed better results when compared to the placebo group.<sup>[13]</sup>

In this case series, 3 PCOS cases registered and treated at the out patient department (OPD) of the National Homoeopathy Research Institute in Mental Health, Kottayam, were evaluated. Symptomatic and significant improvement in USG report after unsuccessful treatment history for more than 5 years in cases of irregular menses since menarche was the prior consideration. During the initial visit the

patients underwent detailed case taking, followed by repertorisation to find the individualized homoeopathic medicines. Indicated remedy was prescribed in centesimal potency (CM) potency according to the principles of homoeopathy based on the totality of symptoms. The cases were analysed and followed by USG scanning.

### **Case Presentation- 1:**

A 30-year-old, obese female presented with irregular menstruation since menarche (at 15 years of age) with a scanty flow for 2 to 3 days and occasional intermittent flow. She also presented with mastalgia before menses. Moreover, she was gaining weight and her BMI was 27.3 kg/m<sup>2</sup>. Also, she complains about primary infertility for 6 years. She had dryness of the vagina and unsatisfactory sexual life. After one year of married life, they took conventional treatment and done ovulation induction treatment for 6 months followed by IUI 5 times without any successful results. They attempted IVF once but were not able to complete it. In family history her mother suffered from bronchial asthma.

Her appetite and thirst were reduced. Occasional urgency with frequent urination and irregular sleep pattern were present. Thermally she was hot. She feared her husband due to his anger. Moreover, she was suffering from itching of skin from exposure to sun and recurrent headaches of shifting nature which was relieved by a tight bandage.

## **Totality of symptoms**

Suppressed emotions.

No sexual satisfaction.

Pain in the breast before menses.

Scanty menses.

Abdomen distension.>flatus.

The treatment started with *NatrumMur*200, one dose per week and later changed to *Lycopodiumclavatum*200, one dose per week ,based on the totality of the symptoms. During treatment, her menses became regular and her general health improved. On subsequent USG





investigation, the ovaries were found to be normal. Detailed follow-up is given in Table 1: Timeline of case 1 and the repertorisation chart is given in Fig.1

As per modified Naranjo criteria total score was+8 (for criteria1,2,5,8,9,10) with zero score for 3,4,6a,6b,7. Modified Naranjo is attached in Table 4.

### **Case Presentation- 2:**

A 32-year-old woman presented at the OPD with irregular menses from menarche. She suffered from secondary amenorrhoea for a period of 4 months followed by profuse and protracted clotted menses which lasted for 8 to 10 days. She gained weight with a BMI of 25.6 Kg/m².Her treatment history includes one year of conventional treatment followed by 6 months of ayurvedic treatment. She had a history of an appendectomy at 20 years of age. Her mother died of brain tumour.

Her appetite was good. Also, constipation and haemorrhoid were present and haemorrhoids are aggravated during menses. Thermally she was ambithermal. Moreover, she complained of recurrent headache with pricking type of pain which got aggravated during exertion, mental worries (frequency increases), and at night. Her anxiety was felt in the stomach region.

# **Totality of symptoms**

Anxious about her disease.

Haemorrhoids during menses.

Headache increased by mental exertion and at night.

Menses is irregular, profuse, protracted, and clotted.

The treatment was started with *Lachesis* 200, one dose per week, based on the totality of symptoms followed by *Lycopodiumclavatum* 200, one dose per week. Detailed follow-up is given in Table2: Timeline of case 2and a repertorisation chart is given in figure 2.

The patient's total score on modified Naranjo

criteria was+9(for criteria1,2,4,5,8,9,10) with zero score for 3,6a,6b,7. Details of modified Naranjo are given in Table 4.

### **Case Presentation-3:**

A 22-year-old female presented with irregular menses from menarche. She dysmenorrhoea during the first three days of menses, a tendency to obesity (BMI: 26 Kg/m<sup>2</sup>), and hirsutism on the chin, upper lips, around the areola, and lower abdomen. Also, she suffered from headaches before menses and leucorrhoea before and after menses. She achieved menarche at 13 years of age. Thereafter, her menses would get delayed by 45- 60 days. Gradually complained of the absence of menses for more than 6 months for about 1 year and she was under Conventional treatment.

She had a history of chickenpox at the age of 18 years. Her father is suffering from hypertension, diabetes mellitus, and renal calculi. Her mother has diabetes mellitus. The Patient had a good appetite but was thirst less and used to drink small quantities of cold water at frequent intervals. Moreover, she had desire for eggs.

## **Totality of symptoms**

Thirst-reduced, she prefers cold drinks.

Desires egg

Leucorrhoea before and after menses.

Headache before menses.

Tendency to obesity.

Pulsatilla200, one dose per week was prescribed for the case. The patient became better symptomatically and on subsequent sonography, the ovaries were found to be normal. Detailed follow-up is given in Table 3 Timeline of case 3 and the repertorisation chart is represented in figure-3.

Modified Naranjo Criteria as proposed by the HPUS Clinical Data Working Group (status December 2015) Maximum score = 13 Minimum score = -3.



# **Table 1: Timeline of case 1:**

| Date              | Symptoms  | Prescription                                 |
|-------------------|---|--|
| 09 June 2016      | Baseline consultation. LMP: 01 June 2016.   | Natrummur 200/ 4 dose (1 dose/week)          |
| 01 July 2016      | Patient improving. Pain in the abdomen due to gaseous distension, >by passing flatus. Generals-good. LMP: 01 July 2016. | Lycopodiumclavatum 200/ 4 dose (1 dose/week) |
| 12 August 2016    | Pain in the abdomen was relieved. Intermittent headache. Generals-good. LMP: 01 August 2016. Flow for 3 days.           | Lycopodiumclavatum 200/ 4 dose (1 dose/week) |
| 08 September 2016 | Headache persists. Intermittent throat irritation >warm drinks. Generals-good. LMP: 29 August 2016.                     | Lycopodiumclavatum 200/ 4 dose (1 dose/week) |
| 01 October 2016   | Patient improving. Generals-good. LMP: 29<br>September 2016.  | Sac lac/ 4 dose (1 dose/week)                |
| November 2016     | Patient improving. Generals-good.   | Sac lac/ 4 dose (1 dose/week)                |
| 02 December 2016  | Menses regular. Weight-67kg. BMI-26.1 Kg/m <sup>2</sup> . Generals-good.  | Sac lac/ 4 dose (1 dose/week)                |

# **Table 2: Timeline of case 2:**

| Date              | Symptoms   | Medicine                     |
|-------------------|--|------------------------------|
| 11 August 2016    | Baseline consultation. Haemorrhoids <during< td=""><td>Lachesismutus 30/4 dose</td></during<>                | Lachesismutus 30/4 dose      |
|                   | menses. Generals-good. PMP: 16 July 2016.  | (1 dose/week)                |
|                   | LMP: 06 August 2016.   |                              |
| 22 September 2016 | Haemorrhoids' persist <during in<="" menses.="" pain="" td=""><td>Lachesismutus 200/ 4 dose (1</td></during> | Lachesismutus 200/ 4 dose (1 |
|                   | back <walking. 06="" 2016.<="" august="" lmp:="" td=""><td>dose/week)</td></walking.>                        | dose/week)                   |
| 06 October 2016   | Haemorrhoids' persist < during menses.   | Lachesismutus 200/ 4 dose (1 |
|                   | Leucorrhoea <menses 30<="" after.="" pmp:="" td=""><td>dose/week)</td></menses>                              | dose/week)                   |
|                   | September 2016. Menses- clotted, profuse,  |                              |
|                   | flow for 7 days, dark blood. LMP: 05 October   |                              |
|                   | 2016.  |                              |
| 24 November 2016  | Haemorrhoids' persist, <menses during.<="" td=""><td>Lachesismutus 200/ 4 dose (1</td></menses>              | Lachesismutus 200/ 4 dose (1 |
|                   | Leucorrhoea persist-watery, corrosive with   | dose/week)                   |
|                   | itching forms long strings. LMP: 24 November   |                              |
|                   | 2016.  |                              |
| 23 December 2016  | Patient improving. Generals-good.  | Lachesismutus 200/ 4 dose (1 |
|                   |  | dose/week)                   |
| 06 January 2017   | Patient improving. Leucorrhoea reduced,  | Lycopodiumclavatum 200/ 4    |
|                   | itching relived. Pain in the right side of the   | dose (1 dose/week)           |
|                   | abdomen. LMP: 24 November 2016.  |                              |
| 02 March 2017     | Patient improving. Leucorrhoea reduced.  | Lycopodiumclavatum 200/ 4    |
|                   | Hemorrhoids reduced. Generals-good. PMP:   | dose (1 dose/week)           |
|                   | 18 January 2017. LMP: 17 February 2017.  |                              |
| 07 April 2017     | Patient improving. Leucorrhoea reduced.  | Lycopodiumclavatum 200/ 4    |





|                   | Hemorrhoids reduced. Generals-good. PMP:       | dose (1 dose/week)              |
|-------------------|--|---------------------------------|
|                   | 11 March 2017. LMP: 01 April 2017. Profuse     |                                 |
|                   | bleeding with pain in the right lower abdomen. |                                 |
| 14 September 2017 | Dysmenorrhoea-profuse flow with clots.         | Sac lac/ 8 dose(2 dose/week)    |
|                   | Burning while urination reduced. Leucorrhoea   |                                 |
|                   | reduced. LMP: 07 September 2017.               |                                 |
| 06 October 2017   | Leucorrhoea reduced. Burning while             | Sac lac/ 12 dose (3 dose/week)  |
|                   | micturition.                                   |                                 |
| 17 November 2017  | Burning while micturition relieved. LMP: 06    | Sac lac/ 8 dose (2 dose/week)   |
|                   | October 2017. Flow for 7 days with clots,      |                                 |
|                   | brown color, pain in the abdomen and back in   |                                 |
|                   | first 2 days, pain increased with flow.        |                                 |
|                   | Generals-good.                                 |                                 |
| 22 December 2017  | LMP: 19 December 2017. Profuse bleeding,       | Sac lac / 4 dose (1 dose/ week) |
|                   | dark clotted blood. Dysmenorrhoea with         |                                 |
|                   | frequent urge to pass stool. Pain in the right |                                 |
|                   | lower abdomen.                                 |                                 |
| 01 February 2018  | Patient improving. LMP: 16 January 2018.       | Sac lac/ 4 dose (1 dose/ week)  |
|                   | Flow for 4 days. Dysmenorrhoea reduced in      |                                 |
|                   | intensity. Weight-60kg. BMI-23.4               |                                 |
|                   | Kg/m <sup>2</sup> .Generals-good.              |                                 |

**Table 3: Timeline of case 3:** 

| Date             | Symptoms                                     | Medicine                   |
|------------------|--|----------------------------|
| 20 January 2016  | Base line consultation. LMP: 27 December     | Calcarea carb 200/ 4 dose  |
|                  | 2015. PMP: 24 November 2015.                 | (1dose/week)               |
| 22 February 2016 | LMP: 28 January 2016. Flow for 4 days.       | Calcarea carb 200/ 4 dose  |
|                  | Leucorrhoea before and after menses.         | (1dose/week)               |
|                  | Generals-good.                               |                            |
| 23 March 2016    | LMP: 01 March 2016. Scanty flow.             | Calcarea carb-200/ 4 dose  |
|                  | Leucorrhoea-white, profuse before and after  | (1dose/week)               |
|                  | menses.                                      |                            |
| 06 June 2016     | LMP: 05 June 2016. Scanty, intermittent flow | Pulsatillanigricans 200/ 4 |
|                  | for 1-2 days.                                | dose (1dose/week)          |
| 13 July 2016     | Menses almost regular. Scanty flow.          | Pulsatillanigricans 200/ 4 |
|                  |  | dose (1dose/week)          |
| 29 August 2016   | LMP: 09 August 2016. Scanty flow for 3 days. | Sac lac/ 10 dose           |
|                  |  | (2 dose/week)              |
| 03 October 2016  | LMP: 09 September 2016. Flow for 3 days.     | Sac lac/ 10 dose           |
|                  |  | (2 dose/week)              |
| 31 October 2016  | LMP: 10 October 2016. Dysmenorrhoea. Flow    | Pulsatillanigricans 200/ 4 |
|                  | for 4 days. Weight-62kg. BMI-24.8.           | dose (1dose/week)          |
| 28 December 2016 | LMP: 15 December 2016. Flow for 2 days. No   | Pulsatillanigricans 200/ 4 |
|                  | dysmenorrhoea.                               | dose (1dose/week)          |





# Table 4: Modified Naranjo criteria:

| Questions   | Case-1 | Case-2 | Case-3 |
|---|--------|--------|--------|
| 1. Was there an improvement in the main symptom or condition for      |        | +2     | +2     |
| which the homeopathic medicine was prescribed?                        |        |        |        |
| 2. Did the clinical improvement occur within a plausible timeframe    | +1     | +1     | +1     |
| relative to the drug intake?  |        |        |        |
| 3. Was there an initial aggravation of symptoms?                      | 0      | 0      | 0      |
| 4. Did the effect encompass more than the main symptom or             | 0      | +1     | 0      |
| condition (i.e., were other symptoms ultimately improved or           |        |        |        |
| changed)?   |        |        |        |
| 5. Did overall well-being improve?                                    | +1     | +1     | +1     |
| 6A Direction of cure: did some symptoms improve in the opposite       | 0      | 0      | 0      |
| order of the development of symptoms of the disease?                  |        |        |        |
| 6B Direction of cure: did at least two of the following aspects apply | 0      | 0      | 0      |
| to the order of improvement of symptoms: -from organs of more         |        |        |        |
| importance to those of less importance? -from deeper to more          |        |        |        |
| superficial aspects of the individual? –from the top downwards?       |        |        |        |
| 7. Did "old symptoms" (defined as non-seasonal and non-cyclical       | 0      | 0      | 0      |
| symptoms that were previously thought to have resolved) reappear      |        |        |        |
| temporarily during improvement?                                       |        |        |        |
| 8. Are there alternate causes (other than the medicine) that—with a   | +1     | +1     | +1     |
| high probability- could have caused the improvement? (Consider the    |        |        |        |
| known course of the disease, other forms of treatment, and other      |        |        |        |
| clinically relevant interventions)                                    |        |        |        |
| 9. Was the health improvement confirmed by any objective              | +2     | +2     | +2     |
| evidence?   |        |        |        |
| 10. Did repeat dosing, if conducted, create similar clinical          | 1      | 1      | 1      |
| improvement?  |        |        |        |
| TOTAL SCORE   | 8      | 9      | 8      |




Figure-1: Repertory chart for case 1






Figure-2: Repertorisation chart for case 2





Figure-3: Repertorisation chart for case-3

# **USG reports BT and AT:**

| Case   | BT Report   | AT Report  |
|--------|---|--|
| Case-1 | Both ovaries are mildly enlarged, with multiple cysts showing polycystic pattern  | Both ovaries show normal appearance.   |
| Case-2 | Polycystic changes noted in both ovaries  | Both ovaries are normal in size with small follicle  |
| Case-3 | Bilateral polycystic ovaries  | Both ovaries normal in size, right ovary shows a dominant follicle of 11mm.  |
|        | ENGAR P. O., MADUKKAMODOU, CHANGANACHERRY PH: 0481-2722808, 2724043  ULTRASOUND STUDY OF ABDOMER & PELVIS  Name Refered by Dr. Dr. Archama Age: 21 Sex: F. Date: 11/4/15  Liver  Live | ST.THOMAS HOSPITAL CHETHIPUZHA CHETHIPUZHA Chemical Chemi |





#### **Result and Discussion:**

In the first and third cases, the total score as per modified Naranjo criteria is +8. In the second case, it is +9.

Among the reproductive phase of women, PCOS is becoming a common problem [14]so evaluation of the condition is done at the earliest to identify the cause to provide an effective treatment. A sedentary lifestyle with lack of exercise and changes in food habits contribute significantly to the development of PCOS. Homeopathic medicines with regular exercise and changes in food habits will give additional benefits. In all 3 cases, patients had to take menstruation-inducing drugs regularly every month, with steroids which produced side effects like obesity. All the patients treated with individualized homeopathic medicines didn't report any untoward reactions from medicines. We were able to produce changes on both the functional level and structural level. There was a disappearance of ovarian pathology in USG after homeopathic treatment. In first case, as per modified Naranjo criteria total score was +8 (for criteria1,2,5,8,9,10) with zero score for 3,4,6a,6b,7.. Detailing of these scores – for criteria 1 and 2 (improvement of the main symptom in a plausible period with homoeopathic treatment), 8 (no other forms of treatment and other clinically relevant interventions were taken), 9 (improvement were documented before and after treatment with USG) - suggests clinical improvement of the patient, 10 (repeat dosing, if concluded, will create similar clinical improvement) No aggravation of symptoms were recorded nor did old symptoms reappear. This can be concluded as there is a causal attribution of treatment to the disease condition.

In the second case, the patient's total score on modified Naranjo criteria was +9 (for criteria1,2,4,5,8,9,10) with zero scores for 3,6a,6b,7. Detailing of these scores – for criteria 1 and 2 (improvement of the main symptom in a plausible period with homeopathic treatment)8 (no other forms of

treatment and other clinically relevant interventions were taken), 9 (improvement were documented before and after treatment with USG),10 (repeat dosing, if concluded, will create similar clinical improvement) suggests clinical improvement of the patient. No initial aggravation of symptoms was recorded nor did old unresolved symptoms reappear. This can be concluded that the clinical improvement can be attributed to homeopathic treatment.

In the third case, the patients total score on criteria modified Naranjo was+8 (for criteria1.2.5.8.9) with zero score for 3,4,6a,6b,7.Detailing of these scores –for criteria 1 and 2 (improvement of the main symptom in a plausible period homeopathic treatment), 8 (no other forms of treatment and other clinically interventions were taken), 9 (improvement were documented before and after treatment with USG),10 (repeat dosing, if concluded, will create similar clinical improvement) suggests clinical improvement of the patient. No aggravations of symptoms were recorded, the direction of cure was not established nor did old symptoms reappear. As such, based on modified Naranjo criteria scoring, the patient's improvement is attributable to the treatment. Modified Naranjo is attached in Table A. The cases were observed further for 2 years without suggesting the recurrence, indicated homoeopathic medicines can prevent its recurrence.

On comparing The Polycystic Ovarian Syndrome Health related Quality of Life Questionnaire (PCOSQ) there was an improvement in the five domains like emotions, body hair, body weight, infertility, and menstrual problems. They got regular menstruation even without the use of hormone therapies. Depression and anxiety counterparts of PCOS, which can affect their quality of life. Continuous thinking about the disease can produce a negative impact on the individual.[15]Homoeopathic medicines being holistic considers the physical, mental and



emotional aspects which help to improve their state at every level.

In the first case on considering the suppression of emotions with physical ailments like dryness of the vagina, NatMur was prescribed later considering her abdominal ailments it was followed by Lycopodium and pulsatilla, while in 2<sup>nd</sup> case on considering the totality *Lachesis* followed by Lycopodium showed good results. In the third case on considering her desires for egg and cold drinks, Calcarea carb was prescribed later followed by Pulsatilla due to scanty flow of menses. In Lamba, et al, study the commonly indicated medicines were Pulsatilla, Calcarea Carb, and Lycopodium These case reports suggest homoeopathy is useful for PCOS cases.

### **Conclusion:**

This study concludes that individualized homoeopathic treatment can significantly manage PCOS cases, which can produce changes at functional and pathological levels. Homoeopathic medicines along with life style modifications will be more beneficial in the treatment of these cases. Further large sample studies should be done to re-evaluate the effectiveness.

### **Consent of Patient:**

The patient's consent was dully taken for registration as ethics for treatment and publication without disclosing the patient's identity.

## **Limitation of study:**

The same intervention may be tried in more cases for its scientific outcome.

### **Acknowledgement:**

The authors would like to acknowledge Dr. B.S.J. Raja Kumar, Officer in Charge, National Homoeopathy Research Institute in Mental Health, Dr. K.C. Muraleedharan Assistant Director, National Homoeopathy Research Institute in Mental Health, Kottayam, for

providing technical and administrative support from time to time.

#### References:

- 1. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What's new. Adv Clin Exp Med. 2017;26(2):359-67.
- Morgante G, Massaro MG, Di Sabatino A, Cappelli V, De Leo V. Therapeutic approach for metabolic disorders and infertility in women with PCOS. Gynecological Endocrinology. 2018 ;34(1):4-9.
- 3. Mobeen H, Afzal N, Kashif M. Polycystic ovary syndrome may be an autoimmune disorder. Scientifica. 2016;2016.
- 4. Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. European journal of obstetrics &gynecology and reproductive biology: X. 2019;3:100060.
- 5. Bulsara JP, Patel P, Soni A, Acharya S. A review on brief insight into Polycystic Ovarian syndrome. Endocrine and Metabolic Science. 2021:100085.
- 6. Rath P. Management of PCOS through Homoeopathy-A case report. Indian J Res Homoeopathy 2018; 12:95-100.
- 7. Lamba CD, Oberai P, Manchanda RK, Rath P, Bindu PH, Padmanabhan M. Evaluation of homoeopathic treatment in polycystic ovary syndrome: A single-blind, randomized, placebo-controlled pilot study. Indian J Res Homoeopathy 2018; 12:35-45.
- 8. Radha P, Devi RS, Madhavi J. Comparative study of prevalence of polycystic ovarian syndrome in rural and urban population. Journal of Advanced Medical and Dental Sciences Research. 2016;4(2):90.
- Moghadam ZB, Fereidooni B, Saffari M, Montazeri A. Measures of health-related quality of life in PCOS women: a





- systematic review. International journal of women's health.2018; 10:397.
- Tabassum F, Jyoti C, Sinha HH, Dhar K, Akhtar MS. Impact of polycystic ovary syndrome on quality of life of women in correlation to age, basal metabolic index, education, and marriage. PloS one. 2021; 16(3):e0247486.
- 11. Thara C, Divakar SU. Assessment of nutritional status of PCOS women in Kerala.International Journal of Applied Home Science. 2017;4(9-10):717-22.
- 12. ESHRE TR, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and sterility. 2004;81(1):19-25.
- 13. Shetty D, Chandrasekaran B, Singh AW, Oliverraj J. Exercise in polycystic ovarian syndrome: An evidence-based review. Saudi Journal of Sports Medicine. 2017;17(3):123.
- 14. De Frène V, Verhofstadt L, Lammertyn J, Stuyver I, Buysse A, De Sutter P. Quality of life and body mass index in overweight adult women with polycystic ovary syndrome during a lifestyle modification program. Journal of Obstetric, Gynecologic& Neonatal Nursing. 2015;44(5):587-99.
- 15. Podfigurna-Stopa A, Luisi S, Regini C, Katulski K, Centini G, Meczekalski B, et al. Mood disorders and quality of life in polycystic ovary syndrome. Gynecol Endocrinol 2015;31:431-4.

**Conflict of interest:** Author declares that there is no conflict of interest.

**Guarantor** Corresponding author is guarantor of this article and its contents.

**Source of upport:** None

#### How to cit this article:

Bhuvaneswari R, Ravindran NP. Usefulness of Homoeopathic medicines in Poly-cystic ovarian syndrome- Case series. Int. J. AYUSH CaRe. 2021; 5(4):333-342.